Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KHFFZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PF-06263507
|
|||||
| Synonyms |
PF-06263507; A1mcMMAF; A1-mafodotin
Click to Show/Hide
|
|||||
| Organization |
Oxford BioMedica (Top20 MNC) (Originator);Pfizer (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
PF-06281192
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
MMAF
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Maleimido-caproyl
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
mafodotin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 0.8 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 2.4 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 4 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 9.5 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 21.2 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 45.5 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 65.7 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 102.9 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 142 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 109.1 | ug/kg |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1.8 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 10.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 24.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 52.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 90.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 123.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 418.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 486.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg, AUCinf.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 1.8 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 10.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 24.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 52.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 90.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 123.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 418.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 486.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg, AUCinf.
|
[1] |
| Volume of Distribution (Vd) | 9.5 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 3.5 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 6.2 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 6.3 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 5 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 5.5 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 4.2 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 5.3 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 5.6 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 7.4 | L |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 1.8 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 10.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 24.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 52.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 90.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 123.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 418.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 486.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg, AUCinf.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 1.8 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 10.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 24.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 52.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 90.4 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 123.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 418.3 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.7 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg, AUCinf.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 486.2 | day*ug/mL |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg, AUCinf.
|
[1] |
| Elimination Half-Life (t1/2) | 3 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 1.5 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 4.5 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 3.5 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 4.4 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 3.8 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 4.2 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 6 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 5.4 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 5.5 | day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg.
|
[1] |
| Clearance (CL) | 3.4 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.05 mg/kg.
|
[1] |
| Clearance (CL) | 1.7 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.10 mg/kg.
|
[1] |
| Clearance (CL) | 1.5 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.19 mg/kg.
|
[1] |
| Clearance (CL) | 1.5 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.37 mg/kg.
|
[1] |
| Clearance (CL) | 1 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 0.73 mg/kg.
|
[1] |
| Clearance (CL) | 1.3 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 1.42 mg/kg.
|
[1] |
| Clearance (CL) | 0.9 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 2.78 mg/kg.
|
[1] |
| Clearance (CL) | 0.7 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 4.34 mg/kg.
|
[1] |
| Clearance (CL) | 1 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 5.42 mg/kg.
|
[1] |
| Clearance (CL) | 1.1 | L/day |
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors, 6.50 mg/kg.
|
[1] |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
| Standard Type | NCT Number | Clinical Status | Clinical Trial Description |
|---|---|---|---|
| stable disease (SD) | NCT01891669 |
PHASE1
|
A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS
|
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 71.7
|
%
|
Lung cancer cells
|
Lung cancer
|
| Tumor Growth Inhibition value (TGI) |
≈ 100
|
%
|
Lung cancer cells
|
Lung cancer
|
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
7.60%
|
|||
| Patients Enrolled |
Eligible participants had advanced/metastatic solid tumors refractory to standard therapy, ECOG 0-1, and adequate organ function. Exclusion criteria included uncontrolled brain metastases, recent major surgery/anticancer therapy, and active infections.
|
||||
| Administration Dosage |
Drug: PF-06263507 Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined. Drug: PF-06263507 Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01891669 | Clinical Status | PHASE1 | ||
| Clinical Description | A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS | ||||
| Primary Endpoint |
The study assessed dose-limiting toxicities (DLTs) occurring within the first treatment cycle (21 days), including severe neutropenia, febrile neutropenia, thrombocytopenia with bleeding, non-hematologic toxicities, or cardiac troponin abnormalities. AEs were graded per CTCAE v4.0, and persistent toxicity delaying treatment by >2 weeks was considered a DLT.
Click to Show/Hide
|
||||
| Other Endpoint |
Treatment-emergent adverse events (TEAEs) and treatment-related AEs were monitored from baseline through treatment cycles and follow-up, with severity graded per NCI CTCAE v4.0. Hematologic, chemistry, and urine protein abnormalities were tracked, along with vital sign changes meeting predefined criteria. Anti-drug antibodies and pharmacokinetic parameters (Tmax for PF-06263507 and metabolites) were also evaluated.
Click to Show/Hide
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.70% | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of PF-06263507 was 3 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung cancer | Lung cancer cells | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of PF-06263507 was 10 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung cancer | Lung cancer cells | Homo sapiens | ||
References